Fadi S. Braiteh is a medical oncologist and clinical researcher at Comprehensive Cancer Centers of Nevada (CCCN) where he serves as a principal investigator for numerous research trials though UCLA-TRIO-US and US Oncology Research network, mostly in gastrointestinal and thoracic malignancies. Additionally, Dr. Braiteh directs the Translational Oncology Program (TOP-Phase I) at CCCN for the development of novel anti-cancer agents. He is a certified physician investigator, board certified in internal medicine, palliative medicine and medical oncology with expertise in gastro-intestinal and thoracic oncology.
Prior to CCCN, Dr. Braiteh was the director of Phase I program and developmental therapeutics at the Cancer and Hematology Centers of Western Michigan. During this time, he was a clinical assistant professor of medicine at the School of Human Medicine at Michigan State University, and scientific investigator for Program of Translational Medicine and Phase 1 clinical trials at Van Andel Research Institute in Grand Rapids, Michigan.
Dr. Braiteh is a member of the lecturing faculty with numerous professional societies including American Society of Clinical Oncology, American Medical Association, Academy of Clinical Research Professionals, and Academy of Pharmaceutical Physicians and Investigators. He has authored and co-authored more than 50 original peer-reviewed manuscripts, abstracts and book chapters.
Dr. Braiteh has been featured in The New York Times in relation to his work with gene mutations and he has been repeatedly named among America’s top medical oncologists by Castle-Connolly, US News & World Report and Las Vegas Life. He has also received numerous honors including “Medical Marvel” from Nevada Business magazine, the Patients Top Choice Award, Top Researcher Award, Susan G. Komen for the Cure Award, the M.D. Anderson Cancer Center Employee Achievement Award and the ASCO Foundation Merit Award among others.
Dr. Braiteh received his medical degree from Saint Joseph University in Beirut, Lebanon. Following a residency in internal medicine at the Yale School of Medicine in New Haven, Connecticut, he completed three fellowships in palliative care and hospice medicine, Phase I drug development and medical oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Liver cancer on local TV